2026-04-17T02:02:29Zhttps://recercat.cat/oai/request
oai:recercat.cat:2445/1761422025-11-19T20:22:38Zcom_2072_1057col_2072_478800col_2072_478917
RECERCAT author Alcaraz Asensio, Antonio author Rodríguez Antolín, Alfredo author Carballido Rodríguez, Joaquín author Castro Díaz, David author Esteban Fuertes, Manuel author Cózar Olmo, José M. author Ficarra, Vincenzo author Medina López, Rafael author Fernández Gómez, Jesús M. author Angulo, Javier C. author Medina Polo, José author Brenes Bermúdez, Francisco J. author Molero García, José M. author Fernández Pro Ledesma, Antonio author Manasanch, José author The QUALIPROST Study Group 2021-04-09T13:18:21Z2021-04-09T13:18:21Z2020-09-092021-04-09T13:18:21Z To investigate whether tamsulosin (TAM) and the hexanic extract of Serenoa repens (HESr) are more effective in combination than as monotherapy in men with moderate-to-severe lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH). Subset analysis of data from a 6-month, multicenter observational study. Patients received either tamsulosin (0.4 mg/day) or HESr (320 mg/day) alone or in combination. Primary endpoints were change in symptoms and quality of life. Tolerability was also assessed. Seven hundred and nine patients were available for intention to treat (ITT) analysis, 263 treated with tamsulosin, 262 with HESr, and 184 with TAM + HESr. After 6 months, International Prostate Symptom Score (IPSS) scores improved by a mean (standard deviation) of 7.2 (5.0) points in the TAM + HESr group compared to 5.7 (4.3) points with TAM alone and 5.4 (4.6) points with HESr (p < 0.001). Quality of life showed greatest improvement with combination therapy (p < 0.02). Adverse effects were reported by 1.9% of patients receiving HESr, 13.3% receiving TAM, and 12.0% receiving TAM + HESr (p < 0.001). In men with moderate/severe LUTS/BPH, combination treatment with TAM + HESr produced more effective symptom relief and greater improvement in quality of life than with either treatment alone, with acceptable tolerability. cc-by (c) Alcaraz Asensio, Antonio et al., 2020 http://creativecommons.org/licenses/by/3.0/es info:eu-repo/semantics/openAccess Aparell urinari Hiperplàsia suprarenal congènita Terapèutica Urinary organs Congenital adrenal hyperplasia Therapeutics Clinical Benefit of Tamsulosin and the Hexanic Extract of Serenoa Repens, in Combination or as Monotherapy, in Patients with Moderate/Severe LUTS-BPH: A Subset Analysis of the QUALIPROST Study info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion